J Bines1, R Dienstmann2, R M Obadia3, L G P Branco4, D C Quintella3, T M Castro3, P G Camacho5, F A Soares6, M E F Costa7. 1. Department of Medical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil. Electronic address: jose_bines@yahoo.com. 2. Fred Hutchinson Cancer Research Center, Sage Bionetworks, Seattle, USA. 3. Department of Clinical Research, Instituto Nacional de Câncer, Rio de Janeiro. 4. Department of Medical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil. 5. Neonathology Unit, Hospital Federal de Bonsucesso, Rio de Janeiro. 6. Department of Anatomic Pathology, A.C. Camargo Cancer Center, São Paulo; Faculty of Dentistry, University of São Paulo, São Paulo. 7. Department of Radiology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Abstract
BACKGROUND: As novel treatments carry substantial price tags and are mostly cost-prohibitive in low- and middle-income countries, there is an urgent need to develop alternatives, such as off-patent drugs. Megestrol acetate (MA) has a longstanding history in the treatment of breast cancer, but recently it is being used less often due to the advent of newer agents. PATIENTS AND METHODS: This two-stage phase II trial evaluated the antitumor activity and toxicity of MA in postmenopausal women with hormone-sensitive advanced breast cancer who had experienced disease progression on a third-generation nonsteroidal aromatase inhibitor (NSAI). Eligible patients had metastatic breast cancer treated with a NSAI with at least 6-month progression-free survival (PFS), or relapse after ≥1 year on adjuvant NSAI. Patients received MA at a single daily oral dose of 160 mg. Primary end point was clinical benefit rate (CBR). RESULTS: Forty-eight patients were enrolled. The CBR was 40% [95% confidence interval (CI) 25% to 55%], and the median duration of clinical benefit was 10.0 (95% CI 8.0-14.2) months. The median PFS was 3.9 (95% CI 3.0-4.8) months. The most common grade 3 adverse events were anemia (2%), dyspnea (2%), fatigue (2%), musculoskeletal pain (4%), deep vein thrombosis (10%), and weight gain (2%). CONCLUSIONS: This is the first study to prospectively evaluate the efficacy and safety of MA in postmenopausal women with hormone-sensitive disease progressing on a NSAI. MA has demonstrated activity and acceptable tolerability in this setting, and therefore remains a reasonable treatment option in a cost-sensitive environment. These results also provide the background for further evaluation of progestins in the treatment of breast cancer. CLINICAL TRIALS: local trial number, related to the approval by the IRB: CEP 108/06.
BACKGROUND: As novel treatments carry substantial price tags and are mostly cost-prohibitive in low- and middle-income countries, there is an urgent need to develop alternatives, such as off-patent drugs. Megestrol acetate (MA) has a longstanding history in the treatment of breast cancer, but recently it is being used less often due to the advent of newer agents. PATIENTS AND METHODS: This two-stage phase II trial evaluated the antitumor activity and toxicity of MA in postmenopausal women with hormone-sensitive advanced breast cancer who had experienced disease progression on a third-generation nonsteroidal aromatase inhibitor (NSAI). Eligible patients had metastatic breast cancer treated with a NSAI with at least 6-month progression-free survival (PFS), or relapse after ≥1 year on adjuvant NSAI. Patients received MA at a single daily oral dose of 160 mg. Primary end point was clinical benefit rate (CBR). RESULTS: Forty-eight patients were enrolled. The CBR was 40% [95% confidence interval (CI) 25% to 55%], and the median duration of clinical benefit was 10.0 (95% CI 8.0-14.2) months. The median PFS was 3.9 (95% CI 3.0-4.8) months. The most common grade 3 adverse events were anemia (2%), dyspnea (2%), fatigue (2%), musculoskeletal pain (4%), deep vein thrombosis (10%), and weight gain (2%). CONCLUSIONS: This is the first study to prospectively evaluate the efficacy and safety of MA in postmenopausal women with hormone-sensitive disease progressing on a NSAI. MA has demonstrated activity and acceptable tolerability in this setting, and therefore remains a reasonable treatment option in a cost-sensitive environment. These results also provide the background for further evaluation of progestins in the treatment of breast cancer. CLINICAL TRIALS: local trial number, related to the approval by the IRB: CEP 108/06.
Entities:
Keywords:
breast neoplasm; drug therapy; megestrol acetate
Authors: Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley Journal: Nat Rev Cancer Date: 2016-11-25 Impact factor: 60.716
Authors: Hari Singhal; Marianne E Greene; Allison L Zarnke; Muriel Laine; Rose Al Abosy; Ya-Fang Chang; Anna G Dembo; Kelly Schoenfelt; Raga Vadhi; Xintao Qiu; Prakash Rao; Bindu Santhamma; Hareesh B Nair; Klaus J Nickisch; Henry W Long; Lev Becker; Myles Brown; Geoffrey L Greene Journal: Oncotarget Date: 2017-09-28
Authors: Hisham Mohammed; I Alasdair Russell; Rory Stark; Oscar M Rueda; Theresa E Hickey; Gerard A Tarulli; Aurelien A Serandour; Aurelien A A Serandour; Stephen N Birrell; Alejandra Bruna; Amel Saadi; Suraj Menon; James Hadfield; Michelle Pugh; Ganesh V Raj; Gordon D Brown; Clive D'Santos; Jessica L L Robinson; Grace Silva; Rosalind Launchbury; Charles M Perou; John Stingl; Carlos Caldas; Wayne D Tilley; Jason S Carroll Journal: Nature Date: 2015-07-08 Impact factor: 49.962